Artur Gontarewicz

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Artur Gontarewicz, Stefan Balabanov, Gunhild Keller et al. · Blood · 2008 · 166 citations · Full text

Medicine, Oncology, Pharmacology +11

Inhibition of IL‐6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer

Freya A. Goumas, Reinhild Holmer, Jan‐Hendrik Egberts et al. · International Journal of Cancer · 2015 · 109 citations

Medicine, Oncology, Pharmacology +17

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL–positive leukemias identified by a proteomics approach

Stefan Balabanov, Artur Gontarewicz, Patrick Ziegler et al. · Blood · 2006 · 94 citations · Full text

Life Sciences, Molecular Biology, Oncology +15

Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model

Daniel Benten, Gunhild Keller, Alexander Quaas et al. · Neoplasia · 2009 · 68 citations · Full text

Medicine, Pharmacology, Cancer Pharmacology +9

The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNγ-induced cell death in human ovarian carcinoma cells

Christine Sers, Knut Husmann, Irina Nazarenko et al. · Oncogene · 2002 · 53 citations

Life Sciences, Genetics, Oncology +14